Victoria P. Werth
A5029793095- Systemic Lupus Erythematosus Research
- Inflammatory Myopathies and Dermatomyositis
- Autoimmune Bullous Skin Diseases
- T-cell and B-cell Immunology
- Urticaria and Related Conditions
- Eosinophilic Disorders and Syndromes
- Monoclonal and Polyclonal Antibodies Research
- Dermatology and Skin Diseases
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Systemic Sclerosis and Related Diseases
- Skin Diseases and Diabetes
- Psoriasis: Treatment and Pathogenesis
- Cytokine Signaling Pathways and Interactions
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- Dermatological and Skeletal Disorders
- Platelet Disorders and Treatments
- Peripheral Neuropathies and Disorders
- Atherosclerosis and Cardiovascular Diseases
- Cutaneous lymphoproliferative disorders research
- Celiac Disease Research and Management
- Immunodeficiency and Autoimmune Disorders
- Skin Protection and Aging
- Rheumatoid Arthritis Research and Therapies
- Autoimmune and Inflammatory Disorders
University of Pennsylvania
2016-2025
Philadelphia VA Medical Center
2016-2025
University of Pennsylvania Health System
2004-2025
Hospital of the University of Pennsylvania
2012-2024
Veterans Health Administration
2013-2024
GTx (United States)
2009-2024
Penn Center for AIDS Research
2020-2024
California University of Pennsylvania
2008-2024
Tulane University
2024
Louisiana State University
2024
The Systemic Lupus International Collaborating Clinics (SLICC) group revised and validated the American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification criteria in order to improve clinical relevance, meet stringent methodology requirements, incorporate new knowledge regarding immunology SLE.The were derived from a set 702 expert-rated patient scenarios. Recursive partitioning was used derive an initial rule that simplified refined based on SLICC physician...
<h3>Objective</h3> To develop and validate new classification criteria for adult juvenile idiopathic inflammatory myopathies (IIM) their major subgroups. <h3>Methods</h3> Candidate variables were assembled from published expert opinion using consensus methodology. Data collected 47 rheumatology, dermatology, neurology paediatric clinics worldwide. Several statistical methods used to derive the criteria. <h3>Results</h3> Based on data 976 IIM patients (74% adults; 26% children) 624 non-IIM...
To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in phase IIb, randomized, double-blind, placebo-controlled study adults with moderate-to-severe systemic lupus erythematosus (SLE).Patients (n = 305) were randomized to receive intravenous anifrolumab (300 mg or 1,000 mg) placebo, addition standard therapy, every 4 weeks for 48 weeks. Randomization was stratified by SLE Disease Activity Index 2000 score (<10 ≥10), oral corticosteroid dosage ≥10...
To develop and validate new classification criteria for adult juvenile idiopathic inflammatory myopathies (IIM) their major subgroups.Candidate variables were assembled from published expert opinion using consensus methodology. Data collected 47 rheumatology, dermatology, neurology, pediatric clinics worldwide. Several statistical methods utilized to derive the criteria.Based on data 976 IIM patients (74% adults; 26% children) 624 non-IIM with mimicking conditions (82% 18% children),...
Objectives The efficacy and safety of sifalimumab were assessed in a phase IIb, randomised, double-blind, placebo-controlled study ( NCT01283139 ) adults with moderate to severe active systemic lupus erythematosus (SLE). Methods 431 patients randomised received monthly intravenous (200 mg, 600 mg or 1200 mg) placebo addition standard-of-care medications. Patients stratified by disease activity, interferon gene-signature test (high vs low based on the expression four genes) geographical...
BACKGROUND. Plasmacytoid DCs (pDC) produce large amounts of type I IFN (IFN-I), cytokines convincingly linked to systemic lupus erythematosus (SLE) pathogenesis. BIIB059 is a humanized mAb that binds blood DC antigen 2 (BDCA2), pDC-specific receptor inhibits the production IFN-I and other inflammatory mediators when ligated. A first-in-human study was conducted assess safety, tolerability, pharmacokinetic (PK) pharmacodynamic (PD) effects single doses in healthy volunteers (HV) patients with...
Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but has been lacking. Previously, an international task force consisting representatives medical specialists published framework such definition, without reaching final recommendation. Methods Several systematic literature reviews were performed specific research questions examined suitably chosen data sets. The findings discussed, reformulated...
To assess the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor TYK2, in a phase II trial adult patients with active systemic lupus erythematosus (SLE).
Blood dendritic cell antigen 2 (BDCA2) is a receptor that exclusively expressed on plasmacytoid cells, which are implicated in the pathogenesis of lupus erythematosus. Whether treatment with litifilimab, humanized monoclonal antibody against BDCA2, would be efficacious reducing disease activity patients cutaneous erythematosus has not been extensively studied.In this phase trial, we randomly assigned adults histologically confirmed or without systemic manifestations 1:1:1:1 ratio to receive...
Iberdomide, a cereblon modulator promoting degradation of the transcription factors Ikaros and Aiolos, which affect leukocyte development autoimmunity, is being evaluated for treatment systemic lupus erythematosus (SLE).